19
Views
20
CrossRef citations to date
0
Altmetric
Special Report

Androgen receptor abnormalities in castration-recurrent prostate cancer

&
Pages 417-422 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Álvaro Pinto. (2014) Beyond abiraterone. Cancer Biology & Therapy 15:2, pages 149-155.
Read now
Rong Hu, Samuel R Denmeade & Jun Luo. (2010) Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Review of Endocrinology & Metabolism 5:5, pages 753-764.
Read now

Articles from other publishers (18)

Ana Caroline Hillebrand, Lolita Schneider Pizzolato, Brasil Silva Neto, Gisele Branchini & Ilma Simoni Brum. (2018) Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer. PLOS ONE 13:7, pages e0200613.
Crossref
Fiorella Magani, Stephanie O. Peacock, Meghan A. Rice, Maria J. Martinez, Ann M. Greene, Pablo S. Magani, Rolando Lyles, Jonathan R. Weitz & Kerry L. Burnstein. (2017) Targeting AR Variant–Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. Molecular Cancer Research 15:11, pages 1469-1480.
Crossref
Kenneth C. Valkenburg, Angelo M. De Marzo & Bart O. Williams. (2017) Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression. Oncotarget 8:46, pages 80265-80277.
Crossref
Taylor M. Nguyen & Alexander W. Pastuszak. (2016) Testosterone Therapy Among Prostate Cancer Survivors. Sexual Medicine Reviews 4:4, pages 376-388.
Crossref
Michael W. Drazer & Walter M. Stadler. (2016) The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. The Cancer Journal 22:5, pages 330-333.
Crossref
Tao Wang, Wen Song, Yuan Chen, Ruibao Chen, Zhuo Liu, Licheng Wu, Mingchao Li, Jun Yang, Liang Wang, Jihong Liu, Zhangqun Ye, Chenguang Wang & Ke Chen. (2015) Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling. Clinical Cancer Research 22:6, pages 1531-1544.
Crossref
Michael T. SchweizerEmmanuel S. AntonarakisHao WangA. Seun AjiboyeAvery SpitzHaiyi CaoJun LuoMichael C. HaffnerSrinivasan YegnasubramanianMichael A. CarducciMario A. EisenbergerJohn T. IsaacsSamuel R. Denmeade. (2015) Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine 7:269.
Crossref
Tao Wang, Shuiming Guo, Zhuo Liu, Licheng Wu, Mingchao Li, Jun Yang, Ruibao Chen, Xiaming Liu, Hua Xu, Shaoxin Cai, Hui Chen, Weiyong Li, Shaohua Xu, Liang Wang, Zhiquan Hu, Qianyuan Zhuang, Liping Wang, Kongming Wu, Jihong Liu, Zhangqun Ye, Jun-Yuan Ji, Chenguang Wang & Ke Chen. (2014) CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget 5:21, pages 10293-10306.
Crossref
Juan Fernando Uribe. (2012) Persistent Sexual Dysfunction and 5 Alpha Reductase Inhibitors. The Journal of Sexual Medicine 9:9, pages 2475.
Crossref
Michael T. Schweizer & Emmanuel S. Antonarakis. (2012) Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Therapeutic Advances in Urology 4:4, pages 167-178.
Crossref
A Bryce & C J Ryan. (2011) Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor. Clinical Pharmacology & Therapeutics 91:1, pages 101-108.
Crossref
Yohann Loriot, Christophe Massard & Karim Fizazi. 2012. Management of Prostate Cancer. Management of Prostate Cancer 251 259 .
Christophe Massard & Karim Fizazi. 2012. Advances in Rapid Sex-Steroid Action. Advances in Rapid Sex-Steroid Action 213 223 .
Lucas P. Nacusi & Donald J. Tindall. (2011) Targeting 5α-reductase for prostate cancer prevention and treatment. Nature Reviews Urology 8:7, pages 378-384.
Crossref
Christophe Massard & Karim Fizazi. (2011) Targeting Continued Androgen Receptor Signaling in Prostate Cancer. Clinical Cancer Research 17:12, pages 3876-3883.
Crossref
Kristin R. Lamont & Donald J. Tindall. (2011) Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer. Molecular Endocrinology 25:6, pages 897-907.
Crossref
Oliver Sartor. (2011) Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian Journal of Andrology 13:3, pages 366-368.
Crossref
Timothy C. Thompson. (2010) Grappling with the Androgen Receptor: A New Approach for Treating Advanced Prostate Cancer. Cancer Cell 17:6, pages 525-526.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.